Psoriasis Clinical Trial
Official title:
Characterization of Cutaneous Microbiota and Evaluation of the Antimicrobial Peptides Roles in the Psoriasis Etiopathogenesis
The skin harbors a complex and dynamic microbiota constituted by numerous microorganisms that
live in symbiosis with the host. The specific etiology of psoriasis is still not-well
understood; nonetheless several studies highlighted that that the skin microbiota could have
a pivotal role in the maintenance and/or progression of the disease, acting as microbial
predictor of psoriasis however.
The aim of the present study was to characterize the microbiota of cutaneous biopsies
associated to guttate and vulgaris psoriasis, both considering lesion and healthy skin
belonging to the same psoriatic subject.
Twelve individuals with guttate psoriasis and 12 individuals with vulgaris psoriasis have
been enrolled at Dermatological Unit of IRCCS Galeazzi Institute, Milan.
Patients selected for the psoriasis vulgaris group had a course of disease stable for at
least 1 month before collection. The second group presented guttate psoriasis, defined as
"eruptive", that is characterized by a rapid appearance and worsening of the clinical
presentation within the month preceding the visit.
From each participant, a punch was used to obtain a cutaneous sample from both a lesion and
healthy skin area of 2 mm2 belonging to the left gluteus, for a total of 48 biological
samples. Participants were selected and included in the study according to the following
criteria: i) over 18 years of age; ii) use of a free-preservatives soap with moisturizing
function; iii) no use of probiotics; iv) no use of antibiotics; v) no treatment with
corticosteroids, biological drugs, methotrexate or retinoids in the month prior the sampling;
vi) no use of topical corticosteroids, vitamin D derivatives or phototherapy; vi) no chronic
or systemic infections; vii) no cutaneous acute infections; viii) no allergy to pollen, food
and drugs ix) no pets. Informed consent was obtained from all subjects.
A metagenomics approach, performed by the use of Ion torrent Personal machine, were used to
investigate the bacterial composition of the skin microbiota associated to each samples
collected.
After sequencing, the data analysis were focused on the bacterial biodiversity and microbial
networks existing in the skin microbiota to evaluate a hypothetical role of bacteria in the
complex pathophysiological mechanisms involved in psoriasis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |